

APPENDIX CONTENTS

A Societal impact	15
B Dataset collection details	15
B.1 Systematic review selection	15
B.2 Conclusion to question conversion	16
B.3 Relevant study selection and question validation	16
C Additional dataset distributions	17
D Evaluated models and prompts	17
E LLM instruction-following rates	20
F LLM performance as a function of number of relevant sources	20
G LLM performance as a function of token length of relevant sources	21
H Average confusion matrices for treatment outcome effects	21
I Performance by review publication year	23
J Per-class recall for individual models	23
K Model performance under the expert-guided prompt setup	23
L Model performance under additional prompt variations	23
M Question correctness across models	26
N Performance by medical specialty	26
O Full-text vs abstract sources	26
P Performance with internal memory	28
Q Performance with varying source order	28
R Constrained human baseline evaluation	29
S Qualitative analysis	29
S.1 Deep-dive on Deepseek V3	29
S.2 Additional examples of failure modes	37
T Individual confusion matrices for all models	44

A SOCIETAL IMPACT

The use of large language models to automate systematic reviews offers clear potential to accelerate evidence synthesis in medicine and policy. However, when these systems produce incorrect or misleading results, clinicians and policymakers may base decisions on flawed findings, leading to inappropriate treatments or misguided recommendations.

Our study underscores the urgent need for continued research and cautious deployment. LLM-based systematic review systems need further rigorous validation, transparent uncertainty quantification, and mechanisms to detect and mitigate biases and errors. Only through careful development and oversight can these technologies be harnessed to benefit society without exacerbating existing risks or creating new harms.

B DATASET COLLECTION DETAILS

Below, we provide additional in-depth details regarding stages in dataset curation process.

B.1 SYSTEMATIC REVIEW SELECTION

MedEvidence is originally derived from 6,709 Cochrane publications extracted via Entrez from PubMed. We first discarded any papers where first References subsection was not both entitled “Studies included in this review” and non-empty, as our initial extraction filter included Cochrane SR protocols and SRs finding no valid studies, which were not of interest. We filter for SRs where all included references have a retrievable abstract and limit to SRs with 12 or less references to reduce annotator burden and improve odds of finding SRs where questions can be validated. On average, the end-to-end creation of a single question requires approximately 20 minutes. Appendix Figure 8 presents a cohort diagram for the materialization of the dataset.




Figure 8: MedEvidence cohort diagram describing selection criteria for Cochrane SRs suitable for use in the MedEvidence dataset. Note that not all available papers in the second-to-last stage were manually reviewed for use in the final stage.

Main results

Five RCTs, reported in 12 records, with 462,754 participants, met the inclusion criteria.

We identified trials on whole-cell plus recombinant vaccine (WC-rBS vaccine (Dukoral)) from Peru and trials on bivalent whole-cell vaccine (BivWC (Shanchol)) vaccine from India and Bangladesh. We did not identify any trials on other BivWC vaccines (Euvichol/ Euvichol-Plus), or Hillchol.

Two doses of Dukoral with or without a booster dose reduces cases of cholera at two-year follow-up in a general population of children and adults, and at five-month follow-up in an adult male population (overall VE 76%; RR 0.24, 95% confidence interval (CI) 0.08 to 0.65; 2 trials, 16,423 participants; high-certainty evidence).

Two doses of Shanchol reduces cases of cholera at one-year follow-up (overall VE 37%; RR 0.63, 95% CI 0.47 to 0.85; 2 trials, 241,631 participants; high-certainty evidence), at two-year follow-up (overall VE 64%; RR 0.36, 95% CI 0.16 to 0.81; 2 trials, 168,540 participants; moderate-certainty evidence), and at five-year follow-up (overall VE 80%; RR 0.20, 95% CI 0.15 to 0.26; 1 trial, 54,519 participants; high-certainty evidence).

A single dose of Shanchol reduces cases of cholera at six-month follow-up (overall VE 40%; RR 0.60, 95% CI 0.47 to 0.77; 1 trial, 204,700 participants; high-certainty evidence), and at two-year follow-up (overall VE 39%; RR 0.61, 95% CI 0.53 to 0.70; 1 trial, 204,700 participants; high-certainty evidence).

A single dose of Shanchol also reduces cases of severe dehydrating cholera at six-month follow-up (overall VE 63%; RR 0.37, 95% CI 0.28 to 0.50; 1 trial, 204,700 participants; high-certainty evidence), and at two-year follow-up (overall VE 50%; RR 0.50, 95% CI 0.42 to 0.60; 1 trial, 204,700 participants; high-certainty evidence).

We found no differences in the reporting of adverse events due to vaccination between the vaccine and control/placebo groups.

Figure 9: An example of a “Main Results” section from a Cochrane review used in MedEvidence (DOI: <https://doi.org/10.1002/14651858.CD014573>). Annotators were instructed to extract conclusions from this standardized sub-section of the SR abstract.

B.2 CONCLUSION TO QUESTION CONVERSION

Appendix Figure 9 provides a direct example of a SR abstract parsed for manual question creation. We highlight the explicit statements (‘conclusions’) asserting differences between a treatment and control on an outcome, and the presence of standardized, author-provided assessment of evidence certainty for these individual conclusions. SR abstracts were consistently written in this form, allowing annotators to consistently interpret the conclusion into a question. To define the correct answer to the generated question, annotators obeyed the following criteria:

- Outcomes, or pairs of treatments and controls, where the authors stated that no studies provided sufficient (or any) evidence to perform analysis were labeled as `insufficient data` questions.
- Conclusions in which the authors stated that there was “no difference” or “no significant difference” between treatments and controls were labeled as `no difference` questions.
- Conclusions where the authors stated a difference between outcomes either definitively or with qualification (e.g. ‘X increases Y’ or ‘X may reduce Y’) were given the appropriate `higher` or `lower` label.
- Conclusions where the authors expressed that uncertainty was too great to evaluate a treatment outcome effect were placed in the `uncertain effect` label class. Conclusions where authors assessed a difference, but then stated that they were very uncertain of their findings were deemed ambiguous and discarded.

B.3 RELEVANT STUDY SELECTION AND QUESTION VALIDATION

For author conclusions where more than one study was used, SRs provide meta-analyses over all relevant sources (an example meta-analysis is shown in Appendix Figure 10), allowing us to confirm whether the studies used in the original SR contain sufficient information to replicate the conclusions of human analysis.




Figure 10: An example meta-analysis from a Cochrane review (figure from DOI: <https://doi.org/10.1002/14651858.CD014573>). Notably, the set of relevant studies and their individual weighted contributions to the overall result are available.

C ADDITIONAL DATASET DISTRIBUTIONS

We present additional statistical characteristics of the questions in our MedEvidence dataset in Appendix Figure 11. We highlight that the dataset is balanced with respect to evidence certainty levels, strengthening the reliability of our main observations on the relationship between evidence certainty and model performance. With regard to the joint distribution of correct treatment outcome effect and evidence certainty, we note that the highly concentrated distributions for the `insufficient` data and `uncertain` effect classes are inherent to the nature of SR. For example, in the case of the `insufficient` data class, authors cannot draw definitive conclusions from analyses they were unable to perform; thus, their findings are most uncertain when the quality of evidence is poor.

D EVALUATED MODELS AND PROMPTS

The full list of 25 models we evaluate on MedEvidence is provided in Appendix Table 3. The exact prompt used to elicit LLM responses for evaluation under the basic prompt regime is provided in Appendix Figure 12. Under the expert-guided prompt regime, models were first instructed to generate a formatted article summary using the summarization step (using Appendix Figure 13a), then asked to provide answers based on the generated summaries for all relevant articles (via Appendix Figure 13b). In all cases, chunks of original article text or previously-generated summarization were provided with a header line containing the article’s title, date of publication (if available), and PubMed ID, allowing the LLM to recognize and assign blocks of content to different sources and synthesize in-context.

Table 3: List of evaluated models with their model size and context length limit we set for our experiments. Precision is 16-bit floating point unless specified otherwise.

Model	Model Type	Parameter Sizes	Context Limit
DeepSeek R1 (DeepSeek-AI, 2025a)	Generalist Reasoning	671B	131K
DeepSeek V3 (DeepSeek-AI, 2025b)	Generalist Non-Reasoning	671B	131K
GPT-4.1 (OpenAI, 2024a)	Generalist Non-Reasoning	Unknown	1M
GPT-4.1 mini (OpenAI, 2024a)	Generalist Non-Reasoning	Unknown	131K
GPT-o1 (OpenAI, 2024b)	Generalist Non-Reasoning	Unknown	150K
GPT-oss-120B (OpenAI et al., 2025)	Generalist Reasoning	120B	128K
HuatuoGPT-o1 (Chen et al., 2024a)	Medical Reasoning	7B, 70B	32K, 16K
Llama 3.0 (AI@Meta, 2024)	Generalist Non-Reasoning	8B, 70B	8K
Llama 3.1 (AI@Meta, 2024)	Generalist Non-Reasoning	8B, 70B, 405B	131K
Llama 3.3 (AI@Meta, 2024)	Generalist Non-Reasoning	70B	131K
Llama 3.3 (R1-Distill) (DeepSeek-AI, 2025a)	Generalist Reasoning	70B	131K
Llama 4 Maverick (AI@Meta, 2025)	Generalist Non-Reasoning	400B (17B active)	500K
Llama 4 Scout (AI@Meta, 2025)	Generalist Non-Reasoning	109B (17B active)	1M
OpenBioLLM (Ankit Pal, 2024)	Medical Non-Reasoning	8B, 70B	8K
OpenThinker2 (Team, 2025a)	Generalist Reasoning	32B	131K
Qwen2.5 (Team, 2025b)	Generalist Non-Reasoning	7B, 32B, 72B	32K
Qwen3 (Team, 2025c)	Generalist Reasoning (hybrid)	235B (22B active, 8-bit)	32 K
QwQ (Team, 2025d)	Generalist Reasoning	32B	131K




Figure 11: Additional statistical characteristics of MedEvidence. (a) shows the dataset distribution stratified by evidence certainty. (b) stratifies the questions by number of relevant sources. (c) is a joint distribution of evidence certainty and correct answer label. (d) shows the distribution of evidence certainties by systematic review publication year.

Given the ARTICLE SUMMARIES. Provide a concise and precise answer to the provided QUESTION.

After you think, return your answer with the following format:

- **Rationale**: Your rationale
- **Full Answer**: A precise answer, citing each fact with the Article ID in brackets (e.g. [2]).
- **Answer**: A final classification exactly matching one of the following options: Higher, Lower, No Difference, Insufficient Data, Uncertain Effect

Think step by step.

QUESTION: {question}

ARTICLE SUMMARIES: {context}

Figure 12: Prompt used to generate LLM responses to questions under the basic prompt setup.

You are the author of a Cochrane Collaboration systematic review, leveraging statistical analysis and assessing risks of bias in order to rigorously assess the effectiveness of medical interventions. As part of your review process, perform the following task:

As a subject expert, (1) summarize the evidence provided by a given ARTICLE as it pertains to a given QUESTION and (2) provide a possible answer.

Otherwise, if the provided article contains relevant information, you must return a list including the following items:

- ****Study Design****: Type of study, level of evidence, and grade of recommendation according to the levels of evidence REC TABLE (provided Below).
- ****Study Population****: Study size and patient population.
- ****Summary****: A concise but comprehensive summary based on the previously specified information, with a focus on the main findings.
- ****Possible Answer****: A concise feasible answer given the evidence.

****REC TABLE ****: Levels of Evidence (from strongest [1a] to lowest [5]).

Grade of Recommendation	Level of Evidence	Type of Study
A	1a	Systematic review and meta-analysis of (homogeneous) randomized controlled trials
A	1b	Individual randomized controlled trials (with narrow confidence intervals)
B	2a	Systematic review of (homogeneous) cohort studies of 'exposed' and 'unexposed' subjects
B	2b	Individual cohort study / low-quality randomized control studies
B	3a	Systematic review of (homogeneous) case-control studies
B	3b	Individual case-control studies
C	4	Case series, low-quality cohort or case-control studies, or case reports
D	5	Expert opinions based on non-systematic reviews of results or mechanistic studies

Think step by step.

****QUESTION****: {question}

****ARTICLE TITLE****: {title}

****ARTICLE CONTENT****: {context}

(a) Prompt used for the summarization step.

You are the author of a Cochrane Collaboration systematic review, leveraging statistical analysis and assessing risks of bias in order to rigorously assess the effectiveness of medical interventions. As part of your review process, perform the following task:

Given the ARTICLE SUMMARIES. Provide a concise and precise answer to the provided QUESTION.

After you think, return your answer with the following format:

- ****Rationale****: Your rationale
- ****Full Answer****: A precise answer, citing each fact with the Article ID in brackets (e.g. [2]).
- ****Answer****: A final classification exactly matching one of the following options: Higher, Lower, No Difference, Insufficient Data, Uncertain Effect

Think step by step.

****QUESTION****: {question}

****ARTICLE SUMMARIES****: {context}

(b) Prompt used for the final answer step.

Figure 13: Prompts used to generate LLM responses to questions under the expert-guided prompt setup, designed to attempt to explicitly enforce model awareness of evidence quality and strength.

E LLM INSTRUCTION-FOLLOWING RATES

The rate at which LLMs provided valid answer output of any kind is presented as part of Figure 4. Precisely, we measured the per-model instruction-following rate, i.e. the percentage of questions for which the full “Answer” field in the model’s final output exactly matched one of the defined answer classes (case-insensitive). We note that a substantial portion of models exhibit a high rate of instruction-following failures: OpenBioLLM 8B and 70B; HuatuoGPT-o1 7B and 70B; Llama 4 Maverick and Scout; Llama 3.0 8B; and Llama 3.1 8B all fail to achieve a 60% instruction-following rate, and only Llama 3.3 70B (Instruct and R1-Distill) achieves perfect instruction-following. We highlight that OpenBioLLM 8B has a 0% instruction-following rate. Lastly, we observe that even when significant portion of the outputs are valid, models still have high error rates, with only an average of $58.1(\pm 5.0)\%$ of valid model outputs being correct. These results demonstrate that, while a high instruction-following rate may diminish performance in small models, poor performance cannot be attributed to instruction-following errors alone.

F LLM PERFORMANCE AS A FUNCTION OF NUMBER OF RELEVANT SOURCES

As shown in Appendix Figure 14, we find no clear general trend between the number of relevant sources and model performance. Notably, this includes performance with a single source (no model achieves even 60% accuracy), highlighting challenges in LLMs’ ability to perform systematic review beyond resolving evidence conflicts. The only exceptions to this are the models with the overall poorest performance (colored in red and orange hues, such as HuatuoGPT-o1 7B and Llama 3.0 8B).




Figure 14: Model accuracy as a function of number of relevant sources.




Figure 15: Model performance as a function of the number of tokens in the relevant studies, separated by model size range. Horizontal axis measures the accuracy by 5-quantiles.

G LLM PERFORMANCE AS A FUNCTION OF TOKEN LENGTH OF RELEVANT SOURCES

Given the lack of dependency on the number of sources on average accuracy, we directly investigate the dependency of model performance on the combined token length of all relevant sources; we present these results in Appendix Figure [15](#). As noted in the main analysis, performance consistently declines at high token counts, except for models with over 100B parameters. Notably, 32B models maintain over 50% average accuracy up to the 80–100% quantile (15K tokens and above). By contrast, 70–72B models fall below 50% accuracy around the 60–80% quantile (11–15K tokens). This decline in the 70–72B range is primarily driven by the underperformance of medically finetuned models (HuatuoGPT-o1 and OpenBioLLM).

H AVERAGE CONFUSION MATRICES FOR TREATMENT OUTCOME EFFECTS

We assess which treatment outcome effect classes are most frequently misclassified by visualizing the confusion matrix averaged across all models. As shown in Figure [16](#), we observe that models with lower than 40% accuracy significantly skew the confusion matrix toward invalid outputs. However, when considering exclusively models with above 40% performance, we observe two significant




Figure 16: Average confusion matrices using basic prompts. (a) Average confusion matrix aggregated across all models. (b) Average confusion matrix aggregated across models achieving at least 40% overall accuracy.




Figure 17: Accuracy by publication year

trends. First, models are consistently unwilling to predict `uncertain effect`. Second, models consistently confuse the `uncertain effect` and `no difference` classes.

For completeness, we provide all individual confusion matrices in Appendix Section [T](#).




Figure 18: Per-class recall for each individual model. 95% confidence intervals are calculated via bootstrapping with $N=1000$.

I PERFORMANCE BY REVIEW PUBLICATION YEAR

As shown in Appendix Figure 17, performance steadily declines for more recent publication years, except for 2023 and 2024. These improvements may partially be explained by the fact that the majority of questions from 2024 involve high- or moderate-certainty evidence (as shown in Appendix Figure 11(d)); as a result, these questions are likely easier for models to answer.

J PER-CLASS RECALL FOR INDIVIDUAL MODELS

We present individual model per-class recall in Appendix Figure 18. Notably, all models, without exception, perform poorly on the `uncertain effect` class. We highlight that Llama 3.3 70B-Instruct outperforms all other models on the `higher` and `lower` classes, but its overall accuracy is held back significantly by its poor performance on the `no difference` and `insufficient data` classes.

K MODEL PERFORMANCE UNDER THE EXPERT-GUIDED PROMPT SETUP

To evaluate the dependency of model performance on prompting quality, we leverage an expert-guided prompt setup as described in the main paper and Appendix Section D. Critically, as shown in Appendix Figure 19 and discussed in the main paper, we find that even with a prompt explicitly designed to encourage models to assess the quality of studies, the dependency of model performance on evidence certainty remains. More broadly, as shown in Appendix Figure 20, we find that our more intentionally-designed prompt does not consistently improve model performance; while performance improves for the five models that performed worst under the basic prompt (namely OpenBioLLM 8B, Llama 4 Scout, Llama 3.0 8B, Qwen2.5-7B-Instruct, and HuatuoGPT-o1 7B), we observe that performance actually decreases for several of the models that performed best with the basic prompt, including a nearly 20% drop in performance for DeepSeek V3 (the highest-performing model when using the basic prompt).

L MODEL PERFORMANCE UNDER ADDITIONAL PROMPT VARIATIONS

To further assess whether our results are simply the result of prompting, we evaluate a range of models without chain-of-thought (by default, all our prompts use chain-of-thought) and with different amounts of few-shot examples. As shown in Appendix Table 4, omitting CoT does not provide any significant difference in performance. We do observe in Appendix Table 5 that few-shot evaluation can improve model performance. However, the overall findings remain consistent: across all models, we observe high error rates; zero-shot DeepSeek V3 remains one of the best models; and a performance gap between LLMs and the original human experts persists.

Table 4: Model accuracy with and without chain-of-thought (CoT).

Model	With CoT	No CoT	Delta
Llama 3.0 70B	0.368	0.360	0.008
Qwen2.5-72B-Instruct	0.528	0.512	0.016
GPT-4.1 mini	0.564	0.564	0.000
Llama 3.3 70B (R1-Distill)	0.580	0.576	0.004
DeepSeek V3	0.624	0.604	0.020




Figure 19: Model accuracy at different evidence qualities when using the expert-guided prompt setup. HuatuoGPT-o1 70B and Llama 3.0 70B are omitted as they were not tested on the expert-guided setup.

Table 5: Model accuracy with several levels of few-shot prompting.

Model	0-shot	1-shot	2-shot	3-shot
Llama 4 Maverick	0.448	0.583 (+0.135)	0.583 (+0.135)	0.632 (+0.184)
Llama 3.3 70B-Instruct	0.492	0.555 (+0.063)	0.571 (+0.079)	0.579 (+0.087)
GPT-4.1 mini	0.564	0.619 (+0.055)	0.595 (+0.031)	0.619 (+0.055)
Llama 3.3 70B (R1-Distill)	0.580	0.599 (+0.019)	0.591 (+0.011)	0.591 (+0.011)
DeepSeek V3	0.624	0.567 (−0.057)	0.555 (−0.069)	0.575 (−0.049)




Figure 20: Changes in model performance when using the basic prompt setup versus the expert-guided prompt setup. HuatuoGPT-o1 70B and Llama 3.0 70B are omitted as they were not tested on the expert-guided setup.

M QUESTION CORRECTNESS ACROSS MODELS

As shown in Appendix Figure 21, 53 questions are answered incorrectly by all models, and only 2 are answered correctly by all models (omitting OpenBioLLM 8B, which gets every question wrong). Otherwise, we observe that performance varies significantly across models. A qualitative analysis of these various question types is presented in Appendix Section S.

N PERFORMANCE BY MEDICAL SPECIALTY

Appendix Figure 22 shows average model accuracy stratified by medical specialty. Models perform significantly worse on questions relating to Psychology & Neurology and Surgery relative to other medical specialties, with accuracies of 27.60% (24.58, 30.52) and 34.09% (31.15, 37.03) respectively. The highest average model performance is observed in the Oncology & Hematology specialty, where models achieve an average accuracy of 63.28% (95% CI: 58.33–68.23).

O FULL-TEXT VS ABSTRACT SOURCES

We evaluate how model performance differs when using full-text articles versus abstracts alone, using the basic prompt setup in both cases. The results of this experiment are presented in Appendix Figure 23. We find that most models with the poorest overall performance actually experience a boost in accuracy (as high as 24.8% in the case of HuatuoGPT-o1-70B) when given only abstracts, even though abstracts contain less information. This suggests that some models struggle on our dataset because of an inability to handle long context, as full-text articles are much longer than abstracts alone. By contrast, the best-performing models usually perform better when given access to full-text (DeepSeek R1, for instance, gains 4.8% accuracy with full-text access). We note that, due to licensing constraints in scientific publishing, many existing deployments and evaluations of LLM to answer questions using scientific literature rely solely on abstracts (Lozano et al., 2023; OpenEvidence, 2025). Our analysis demonstrates that access to full article text benefits frontier models, underscoring the urgent need to expand such access. We highlight initiatives promoting this shift—for instance, beginning in 2025, all U.S. federally-funded research must be made freely available, which could significantly enhance the performance of already-deployed models.

To even further investigate this phenomenon, we isolate model performance on questions with different types of sources. As shown in Appendix Table 6, on average, models perform better on questions that use abstracts only as compared to full-text only, demonstrating that current models generally perform worse when provided with the information that would be necessary to replicate full meta-analysis, emphasizing the need for more work on long-context input.




Figure 21: Analyses of model behavior across questions. (a) Questions (columns) that were deemed correct (light blue) or incorrect (black) for each model (rows), sorted by percentage of models with correct responses for that question (x-axis) and by the percentage of questions a model got correct (y-axis). (b) Distribution of questions by the number of models that answered that question correctly.




Figure 22: Average model accuracy across all models (and 95% confidence interval) stratified by medical specialty.




Figure 23: Changes in model performance when providing full-text when available versus always providing only the abstract (basic prompt setup).

Table 6: Model accuracy on questions where the sources are all abstracts, all fulltext, or have a mix of fulltext and abstracts, respectively.

Model	Abstracts only	Fulltext only	Mixed sources
DeepSeek V3	0.638	0.460	0.772
GPT-4.1	0.615	0.524	0.667
DeepSeek R1	0.600	0.524	0.632
Llama 3.3 70B (R1-Distill)	0.638	0.429	0.614
OpenThinker2-32B	0.608	0.460	0.614
QwQ-32B	0.631	0.460	0.526
GPT-4.1 mini	0.608	0.444	0.596
GPT-oss-120B	0.592	0.429	0.596
Llama 3.1 70B	0.600	0.381	0.614
Qwen3-235B-A22B-FP8	0.562	0.460	0.561
Qwen2.5-72B-Instruct	0.592	0.444	0.474
Qwen2.5-32B-Instruct	0.608	0.413	0.439
Llama 3.3 70B-Instruct	0.554	0.365	0.491
Llama 3.1 405B	0.592	0.349	0.421
GPT-o1	0.631	0.302	0.281
Llama 4 Maverick	0.377	0.460	0.596
Llama 3.0 70B	0.577	0.000	0.298
Llama 3.1 8B	0.377	0.333	0.246
HuatuoGPT-o1-70B	0.600	0.032	0.035
OpenBioLLM 70B	0.531	0.000	0.000
HuatuoGPT-o1-7B	0.385	0.016	0.000
Qwen2.5-7B-Instruct	0.269	0.063	0.193
Llama 3.0 8B	0.338	0.000	0.053
Llama 4 Scout	0.169	0.238	0.158
OpenBioLLM 8B	0.000	0.000	0.000
Average	0.504	0.298	0.387

P PERFORMANCE WITH INTERNAL MEMORY

Table 7: Baseline model accuracy using the provided sources (from Figure 4) versus model accuracy using internal memory only.

Model	With Evidence	Memory Only	Delta
Llama 3.0 70B	0.368	0.116	-0.252
Qwen2.5-72B-Instruct	0.528	0.388	-0.140
GPT-4.1 mini	0.564	0.428	-0.136
Llama 3.3 70B (R1-Distill)	0.580	0.396	-0.184
DeepSeek V3	0.624	0.324	-0.300

To evaluate the effects of potential data leakage, we perform a small-scale experiment to quantify if models are able to answer questions in our benchmark (which were newly formulated for the purpose of this work) by prompting them to answer the questions without providing any articles as context. As shown in Appendix Table 7, models perform far worse when asked to answer the questions from memory; this trend is consistent across the range of baseline performances and in models from varying providers, with Llama 3.0 70B even performing worse than random.

Q PERFORMANCE WITH VARYING SOURCE ORDER

To ensure that our results did not depend on limitations of multi-step refinement (especially in questions with full-text articles as evidence), we compare baseline model performance to performance with the sources randomly shuffled to a new order. As shown in Appendix Table 8, randomizing the source order does not result in performance changes beyond the ranges expected by our confidence

Table 8: Accuracy with original order of sources versus randomly shuffled sources.

Model	Original Order	Shuffled	Delta
Llama 3.0 70B	0.368	0.356	+0.012
Qwen2.5-72B-Instruct	0.528	0.500	+0.028
GPT-4.1 mini	0.564	0.548	+0.016
Llama 3.3 70B (R1-Distill)	0.580	0.564	+0.016
DeepSeek V3	0.624	0.572	+0.052

intervals; thus, our results suggest that source order has no statistically-significant effect on model performance.

R CONSTRAINED HUMAN BASELINE EVALUATION

To better benchmark model performance, we evaluate the performance of humans under similar conditions to the models (i.e. short time constraints, with access to only the abstracts when models similarly do not have full-text access). We recruited three external clinicians (with no connection to this work) with diverse specialties (e.g., pediatrics, oncology) and an average of four years of experience. Each clinician answered 20 randomly selected questions using the same inputs provided to the language models (i.e. abstract-only when models would only have abstract access). The average response time was approximately 10 minutes per question and the mean accuracy was 71.67% (min=65%, max=75%). Notably, every question was answered correctly by at least one clinician. Inter-rater agreement was moderate with a Fleiss’ kappa of 0.43.

S QUALITATIVE ANALYSIS

To provide a better qualitative understanding of success and failure modes on our dataset, we explore the outputs (under the basic prompt setup) of our models directly. First, we closely inspect our best-performing model, DeepSeek V3, and provide some commentary on the quality of the model’s output. Specifically, we consider four types of questions: (1) Questions where all models get the answer wrong. (2) Questions where most models are correct, but DeepSeek V3 is incorrect. (3) Questions where most models are correct, including DeepSeek V3. (4) Questions where most models are wrong, but DeepSeek V3 is correct. Second, we investigate additional failure modes demonstrated by the two other best-performing models and the three worst-performing models.

S.1 DEEP-DIVE ON DEEPSEEK V3

S.1.1 QUESTIONS WHERE ALL MODELS ARE WRONG

Question ID 1 - 0/24 models correct

Review PMID: 28660687

Question: Is the short-term rate of overall lymphocyst formation higher, lower, or the same when comparing retroperitoneal drainage to no drainage?

Correct Answer: no difference

PMIDs of Relevant Sources: 9190979, 12214830

DeepSeek V3 Response:

- ****Rationale**:**

- Article ID 9190979 reports that the complication rate, including lymphocyst formation, was significantly higher in the drained group (Group A) compared to the not-drained group (Group B) (P = 0.01). However, sonographic monitoring showed free abdominal fluid (a proxy for lymphocyst formation) in 18% of drained patients vs. 36% of not-drained patients (P = 0.03),

suggesting a lower rate in the drained group. This creates a contradiction in the findings.

- Article ID 12214830 found no significant difference in lymphocyst formation between the drained and not-drained groups ($P = 0.2$), with asymptomatic lymphocysts detected only in the not-drained group (though statistically insignificant).

- **Full Answer**:

- Article ID 9190979 reports a higher complication rate (including lymphocyst-related morbidity) in the drained group [9190979], but sonographic data suggests a lower rate of free abdominal fluid (a proxy for lymphocyst formation) in the drained group (18% vs. 36%, $P = 0.03$) [9190979]. Article ID 12214830 found no significant difference in lymphocyst formation between groups ($P = 0.2$) [12214830]. The evidence is conflicting, with one study suggesting a lower rate and another showing no difference.

- **Answer**: Uncertain Effect

Remarks: In the SR, authors perform meta-analysis and find no overall significant difference between retroperitoneal drainage and no drainage. DeepSeek V3 does not appear to know how to perform any kind of reconciliation. We note that Article 12214830 does not specify the raw number of events under both treatments, but does state that no lymphocysts (i.e. 0) were detected in the drainage group.

Question ID 198 - 0/24 models correct

Review PMID: 35514111

Question: Is the rate of any PCR-positive SARS-CoV-2 infection higher, lower, or the same when comparing test-based attendance to standard 10-day self-isolation?

Correct Answer: uncertain effect

PMIDs of Relevant Sources: 34534517

DeepSeek V3 Response:

- **Rationale**: The study compared daily testing (test-based attendance) with standard 10-day self-isolation for school-based contacts of SARS-CoV-2 cases. The primary outcomes included rates of symptomatic PCR-confirmed infections and COVID-19-related absences. The results showed no significant difference in the rate of symptomatic PCR-confirmed infections between the two groups, with the intervention group (daily testing) being non-inferior to the control group (self-isolation). The adjusted incidence rate ratio (aIRR) for symptomatic PCR-confirmed infections was 0.96 (95% CI -0.751.22), indicating no statistically significant difference.

- **Full Answer**: The rate of PCR-positive SARS-CoV-2 infection was not significantly different when comparing test-based attendance (daily testing) to standard 10-day self-isolation (aIRR 0.96, 95% CI -0.751.22) [34534517].

- **Answer**: No Difference

Remarks: The authors of the SR state that the results are inconclusive for the following reasons: (a) "risk of bias: considerable missing data for PCR-tests for staff (data were available for 76% control schools and 83% intervention schools)" and (b) "imprecision: the confidence intervals are wide and the 95% CI crosses the line of no effect." In this case, the full-text article

is open-source, so LLMs theoretically had access to essentially all the same information as the SR authors, but evidently, none of these concerns are addressed in DeepSeek V3's response. Furthermore, the DeepSeek V3 response focuses only on symptomatic PCR-confirmed infections, demonstrating limitations in its knowledge of medical contexts, as the question calls for an assessment of any PCR positive infections, which includes asymptomatic cases.

Question ID 32 - 0/24 models correct

Review PMID: 26447539

Question: Is subjective fatigue higher, lower, or the same when comparing methylphenidate to placebo?

Correct Answer: no difference

PMIDs of Relevant Sources: 17674415

DeepSeek V3 Response:

- ****Rationale**:** The study (Article ID 17674415) directly compares methylphenidate to placebo in treating fatigue in Parkinson's disease patients. The results show that methylphenidate significantly reduced fatigue scores (FSS and MFI) compared to placebo, where reductions were nonsignificant. This indicates that subjective fatigue is lower with methylphenidate than with placebo.
- ****Full Answer**:** Subjective fatigue is lower with methylphenidate compared to placebo, as evidenced by significant reductions in Fatigue Severity Scale (FSS) and Multidimensional Fatigue Inventory (MFI) scores in the methylphenidate group ($P < 0.04$), while placebo group reductions were nonsignificant [17674415].
- ****Answer**:** Lower

Remarks: This is a relatively challenging question—in the original SR, the authors compare the improvements in FSS in the placebo group directly to the improvements in the treatment group, rather than comparing the two treatment groups separately to their own baselines (which is what the authors of the cited source do). The source's abstract does state that smaller but non-significant improvements were present in the placebo group, albeit without providing numbers. Regardless, the LLM's response reads as a regurgitation of facts and lacks the critical thinking needed to critically assess cited studies.

S.1.2 QUESTIONS WHERE MOST MODELS ARE CORRECT, BUT DEEPSEEK V3 IS WRONG

Question ID 6 - 16/24 models correct

Review PMID: 26346232

Question: Is stroke prevention higher, lower, or the same when comparing Transcatheter Device Closure (TDC) to medical therapy?

Correct Answer: no difference

PMIDs of Relevant Sources: 22417252, 23514285, 23514286

DeepSeek V3 Response:

- ****Rationale**:** The three articles provide mixed evidence on the effectiveness of Transcatheter Device Closure (TDC) compared to medical therapy for stroke prevention in patients with patent foramen ovale (PFO). Article ID 22417252 found no significant difference in stroke prevention between TDC and medical therapy

($P=0.37$ for the primary endpoint). Article ID 23514285 also reported no significant reduction in recurrent embolic events or death with TDC ($P=0.34$ for the primary endpoint). However, Article ID 23514286 showed no significant benefit in the intention-to-treat analysis ($P=0.08$) but did find a significant reduction in recurrent stroke in the per-protocol and as-treated analyses ($P=0.03$ and $P=0.007$, respectively). Given the inconsistency in results across studies and analyses, the overall evidence is not conclusive.

- **Full Answer**: The evidence is mixed. Two studies (Article ID 22417252 and Article ID 23514285) found no significant difference in stroke prevention between TDC and medical therapy [22417252][23514285]. A third study (Article ID 23514286) reported no significant benefit in the intention-to-treat analysis but found TDC superior in per-protocol and as-treated analyses [23514286].

- **Answer**: Uncertain Effect

Remarks: In this case, unlike most models (16/24 to be exact), DeepSeek V3 seems to 'overthink' the question and hone in on a single case where a sub-analysis of in Article 23514286 finds a significant benefit. Notably, SRs typically use intention-to-treat analysis (<https://training.cochrane.org/handbook/current/chapter-06>), which DeepSeek V3 fails to consider. Furthermore, as in previous cases, no clear efforts to perform meta-analysis or aggregate studies are shown in DeepSeek V3's response.

Question ID 106 - 15/24 models correct

Review PMID: 38197546

Question: Is the risk of cholera at two-year follow-up higher, lower, or the same when comparing two doses of Dukoral with or without a booster dose to placebo?

Correct Answer: lower

PMIDs of Relevant Sources: 7967990, 10823767

DeepSeek V3 Response:

- **Rationale**:

- Article ID 7967990 evaluates the short-term efficacy of two doses of WC/rBS cholera vaccine without a booster, showing 86% protective efficacy over a mean follow-up of 18 weeks. However, it does not provide data on long-term (two-year) efficacy or the effect of a booster dose.
- Article ID 10823767 evaluates the two-year efficacy of the same vaccine, comparing two doses (without booster) to three doses (with booster). After two doses, the vaccine showed no efficacy ($VE = -4\%$), but after the booster dose, efficacy increased to 61%. This suggests that the booster dose significantly improves long-term protection compared to two doses alone.

- **Full Answer**:

- Without a booster dose (two doses only), the vaccine showed no protective efficacy ($VE = -4\%$) at two-year follow-up [10823767].
- With a booster dose (three doses), the vaccine demonstrated 61% protective efficacy at two-year follow-up [10823767].
- Therefore, the risk of cholera at two-year follow-up is **higher** with two doses alone compared to two doses plus a booster.

- **Answer**: Higher

Remarks: This is case where DeepSeek V3 seems to fail due to a misinterpretation of the question, although we believe the semantics of this question are unambiguous. DeepSeek V3 does not seem to pick up on the mention of placebo in the question at all.

Question ID 163 - 16/24 models correct

Review PMID: 25739381

Question: Is neonatal mortality higher, lower, or the same when comparing community-led chlorhexidine cord cleansing to community-led dry cord care?

Correct Answer: lower

PMIDs of Relevant Sources: 22322124, 16546539, 22322126

DeepSeek V3 Response:

- **Rationale**: The question asks whether neonatal mortality is higher, lower, or the same when comparing community-led chlorhexidine cord cleansing to community-led dry cord care. The three articles provide evidence from randomized trials in different settings (Bangladesh, Nepal, and Pakistan) comparing chlorhexidine cord cleansing with dry cord care. All three studies report reductions in neonatal mortality with chlorhexidine use, though the magnitude and statistical significance vary.
- **Full Answer**:
 - In Bangladesh, neonatal mortality was lower with single chlorhexidine cleansing (22.5 per 1000 livebirths) compared to dry cord care (28.3 per 1000 livebirths; RR 0.80 [0.65-0.98]) [22322124].
 - In Nepal, neonatal mortality was 24% lower with chlorhexidine (RR 0.76 [0.55-1.04]) compared to dry cord care, with a significant 34% reduction in infants enrolled within 24 hours (RR 0.66 [0.46-0.95]) [16546539].
 - In Pakistan, chlorhexidine cleansing reduced neonatal mortality (RR 0.62 [0.45-0.85]) compared to dry cord care [22322126].
- **Answer**: **Lower**

Remarks: An example of an instruction-following failure for DeepSeekV3 (even though the overall analysis leads to a correct solution).

S.1.3 QUESTIONS WHERE MOST MODELS ARE CORRECT, INCLUDING DEEPSEEK V3

Question ID 160 - 21/24 models correct

Review PMID: 28829911

Question: Is the risk of treatment-related mortality higher, lower, or the same when comparing chemoradiotherapy plus esophagectomy to chemoradiotherapy alone?

Correct Answer: higher

PMIDs of Relevant Sources: 17401004, 15800321

DeepSeek V3 Response:

- **Rationale**: Both articles compare chemoradiotherapy plus esophagectomy (surgery) to chemoradiotherapy alone in patients with locally advanced esophageal cancer. Article ID 17401004

reports a 3-month mortality rate of 9.3% in the surgery group (arm A) compared to 0.8% in the chemoradiation-alone group (arm B), with a statistically significant difference ($P = .002$). Article ID 15800321 similarly reports a significantly higher treatment-related mortality in the surgery group (12.8%) compared to the chemoradiotherapy-alone group (3.5%) ($P = .03$). Both studies consistently demonstrate that adding surgery to chemoradiotherapy increases treatment-related mortality.

- **Full Answer**: The risk of treatment-related mortality is higher when comparing chemoradiotherapy plus esophagectomy to chemoradiotherapy alone, as evidenced by significantly higher mortality rates in the surgery groups (9.3% vs. 0.8% [17401004]; 12.8% vs. 3.5% [15800321]).
- **Answer**: Higher

Remarks: While this question involves multiple sources, both sources individually agree with the overall correct conclusion, making it fairly straightforward to answer; consequently, almost all models get this question correct.

Question ID 214 - 23/24 models correct

Review PMID: 37594020

Question: Is pain relief at 48 hours higher, lower, or the same when comparing NSAIDs to placebo?

Correct Answer: higher

PMIDs of Relevant Sources: 8871138

DeepSeek V3 Response:

- **Rationale**: The study compared ibuprofen (an NSAID) to acetaminophen and placebo for pain relief in children with acute otitis media over 48 hours. The results showed that ibuprofen was statistically superior to placebo ($P < 0.01$) in relieving pain, with 7% of children still suffering pain in the ibuprofen group compared to 25% in the placebo group. There was no significant difference between acetaminophen and placebo for pain relief.
- **Full Answer**: Pain relief at 48 hours was higher with NSAIDs (ibuprofen) compared to placebo, as evidenced by a statistically significant reduction in pain (7% vs. 25% of children still suffering pain, $P < 0.01$) [8871138].
- **Answer**: Higher

Remarks: A straightforward question that all models (except OpenBioLLM 8B) get correct: one source accurately directly reports on relevant findings without conclusions being revised by the SR authors' critical analysis.

S.1.4 QUESTIONS WHERE DEEPSEEK V3 IS CORRECT, DESPITE MOST MODELS BEING WRONG

Question ID 235 - 3/24 models correct

Review PMID: 32104914**Question:** Is quality of life higher, lower, or the same when comparing computerised cognitive training (CCT) of at least 12 weeks to no intervention?**Correct Answer:** insufficient data**PMIDs of Relevant Sources:** 23531885, 25511081, 20418350**DeepSeek V3 Response:**

- ****Rationale**:** The question asks whether quality of life (QoL) is higher, lower, or the same when comparing computerized cognitive training (CCT) of at least 12 weeks to no intervention. The provided articles focus on cognitive and physical performance improvements but do not explicitly measure or report QoL outcomes. Article ID 23531885 discusses cognitive improvements from CCT but does not mention QoL. Article ID 25511081 examines dual-task gait and divided attention but also does not address QoL. Article ID 20418350 evaluates cognitive performance after mental and physical activity interventions but similarly lacks QoL data.
- ****Full Answer**:** None of the articles provide data on quality of life (QoL) outcomes when comparing CCT of at least 12 weeks to no intervention [23531885, 25511081, 20418350].
- ****Answer**:** Insufficient Data

Remarks: DeepSeek V3 correctly recognizes that none of the relevant studies provide direct, quantitative analysis on QoL outcomes; given the very low model correctness rate (3/24), other models likely attempted to apply colloquial definitions of "quality of life" rather than the narrowly-defined medical definition requiring explicit quantitative measurement.

Question ID 89 - 2/24 models correct

Review PMID: 31557310**Question:** Is the incidence of surgical site infection (SSI) for patients undergoing breast cancer surgery without reconstruction higher, lower, or the same when comparing prophylactic antibiotics administered preoperatively to placebo?**Correct Answer:** lower**PMIDs of Relevant Sources:** 7480237, 9776150, 23052809, 10873356, 19673597, 2403655, 2403697**DeepSeek V3 Response:**

- ****Rationale**:** The question asks about the incidence of surgical site infection (SSI) in breast cancer surgery without reconstruction when comparing prophylactic antibiotics to placebo. The relevant articles provide mixed results: some show a significant reduction in SSI with antibiotics (e.g., [7480237], [2403655]), while others show no significant difference (e.g., [23052809], [10873356], [2403697]). Notably, [7480237] specifically highlights a significant reduction in infections for breast surgery, while [2403655] also supports a reduction in infections for breast surgery. However, other studies, such as [23052809] and [10873356], found no significant difference. The variability in results suggests that the effect

may depend on the type of breast surgery (e.g., mastectomy vs. axillary lymph node dissection) or other factors.

- **Full Answer**: The incidence of SSI is **lower** with prophylactic antibiotics compared to placebo in some breast cancer surgeries, as shown by significant reductions in infections in studies involving plastic surgery ([7480237]) and certain breast procedures ([2403655]). However, other studies found no significant difference for modified radical mastectomy ([23052809]), clean elective breast surgery ([10873356]), or mastectomy ([2403697]). The overall evidence suggests a context-dependent effect, with some procedures benefiting from prophylaxis.

- **Answer**: Lower

Remarks: While DeepSeek V3 does get this question right, and shows flashes of attempting deeper reasoning (e.g. the remark that the effect "may depend on the type of breast surgery"), but this analysis is not directly supported by similar statements from the original SR authors. Additionally, there is still no formal aggregation or meta-analysis attempted, and the level of detail in the reasoning provided by DeepSeek V3 makes it hard to tell if the model's predicted answer was made via some form of intuition or if the model just got a bit lucky.

Question ID 173 - 1/24 models correct

Review PMID: 31425604

Question: Is the risk of necrotizing enterocolitis higher, lower, or the same when comparing monitoring of gastric residual volume and quality to only monitoring of gastric residual quality?

Correct Answer: uncertain effect

PMIDs of Relevant Sources: 29866595

DeepSeek V3 Response:

- **Rationale**: The study compared two groups: one where gastric residual volume (GRV) was measured only in the presence of specific clinical signs (study group) and another where GRV was routinely measured (control group). The primary outcome was time to reach full feeding volumes, but secondary outcomes included necrotizing enterocolitis (NEC). The study found no significant differences in NEC incidence between the two groups, with only 2 cases reported in the control group and none in the study group. However, the small sample size (87 infants) and low event rate limit the ability to draw definitive conclusions about NEC risk.
- **Full Answer**: The study found no significant difference in the incidence of necrotizing enterocolitis between the group where gastric residual volume was measured only in the presence of clinical signs (0 cases) and the group where it was routinely measured (2 cases) [29866595]. The small sample size and low event rate suggest uncertainty in the effect.
- **Answer**: Uncertain Effect

Remarks: Even without explicit prompting, DeepSeek V3 recognizes the weakness of the limited sample size/total number of events—the fact that only DeepSeek V3 gets this question correct shows both the current limitations of models' ability to assess uncertainty, as well as the promise that they may be able to do so consistently in the future.

S.2 ADDITIONAL EXAMPLES OF FAILURE MODES

S.2.1 GPT-4.1

Question ID 82 - 1/24 models correct

Review PMID: 31829446**Question:** Is the rate of major complications higher, lower, or the same when comparing restrictive fluid therapy (RFT) to goal-directed fluid therapy (GDFT)?**Correct Answer:** uncertain effect**PMIDs of Relevant Sources:** 26471495, 22710266, 25595308, 25342408, 23132508**GPT-4.1 Response:**- ****Rationale****:

To answer whether the rate of major complications is higher, lower, or the same when comparing restrictive fluid therapy (RFT) to goal-directed fluid therapy (GDFT), we need direct comparisons from randomized controlled trials or similar studies. Four relevant articles are summarized:

1. ****Article 26471495****: Compared GDFT, restrictive (PRESSURE), and standard (CONTROL) fluid therapy in hip/knee replacement. The rate of major complications was 5% (GDFT) vs. 15% (restrictive), but this difference was not statistically significant ($P=0.27$).
2. ****Article 22710266****: Compared GDFT (Doppler) to zero-balance (restrictive) in colorectal surgery. No significant difference in major complications ($P=0.62$).
3. ****Article 25595308****: Compared GDFT to standard (not specifically restrictive) in CRS/HIPEC. GDFT had significantly fewer major complications, but the comparator was standard, not restrictive.
4. ****Article 25342408****: Compared GDFT to restrictive in elective colorectal surgery. Major complications: 2% (GDFT) vs. 8% (restrictive), not statistically significant ($P=0.36$).
5. ****Article 23132508****: Compared GDFT to fluid restriction in colectomy. Number of patients with complications was nearly identical (26 vs. 27; $P=1.000$).

Across these studies, the rate of major complications is numerically lower with GDFT in some cases, but none of the differences between GDFT and restrictive fluid therapy reach statistical significance. Therefore, the evidence consistently shows no significant difference in major complication rates between RFT and GDFT.

- ****Full Answer****:

Multiple randomized controlled trials directly comparing restrictive fluid therapy (RFT) and goal-directed fluid therapy (GDFT) in various surgical settings (colorectal, colectomy, hip/knee replacement) found no statistically significant difference in the rate of major complications between the two approaches. Article 26471495 reported major complication rates of 5% (GDFT) vs. 15% (restrictive), $P=0.27$; Article 22710266 found no significant difference ($P=0.62$); Article 25342408 found 2% (GDFT) vs. 8% (restrictive), $P=0.36$; and Article 23132508 found nearly identical rates (26 vs. 27 patients, $P=1.000$). Thus, the current evidence indicates no difference in major complication rates between RFT and GDFT [26471495] [22710266] [25342408] [23132508].

- ****Answer****: No Difference

Remarks: In the SR, the authors consider the evidence poor because of study limitations, imprecision of results, and indirectness of evidence. Much like DeepSeek V3, GPT-4.1 does not take into consideration any of these potential limitations and assumes the provided results are entirely trustworthy.

Question ID 183 - 0/24 models correct

Review PMID: 30320433

Question: Is the number of fallers higher, lower, or the same when comparing exercise to usual care?

Correct Answer: insufficient data

PMIDs of Relevant Sources: 19335674

GPT-4.1 Response:

- ****Rationale**:** The article reports that women who exercised had fewer falls compared to those who did not exercise. However, it also states that the difference in the number of falls between the two groups was not statistically significant. This means that, while there was a numerical reduction in fallers in the exercise group, the evidence does not support a definitive conclusion that exercise leads to a higher or lower number of fallers compared to usual care.
- ****Full Answer**:** According to Article ID 19335674, women in the exercise group had fewer falls than those in the usual care group, but the difference in the number of falls between the two groups was not statistically significant [19335674].
- ****Answer**:** No Difference

Remarks: The original article discusses only the number of fall events, not the number of patients who fell. GPT-4.1 fails to recognize this distinction, and thus misinterprets the provided data.

S.2.2 DEEPSEEK-R1

Question ID 2 - 13/24 models correct

Review PMID: 25734590

Question: Is the rate of clinician impression of cognitive change higher, lower, or the same when comparing cholinase inhibitors to placebo in patients with MS?

Correct Answer: higher

PMIDs of Relevant Sources: 15534239, 21519001

DeepSeek-R1 Response:

- ****Rationale**:** Two studies (15534239 and 21519001) investigated donepezil (a cholinesterase inhibitor) versus placebo in MS patients. The first study (15534239) reported a statistically significant higher clinician-reported cognitive improvement with donepezil ($p = 0.036$). The second, larger multicenter study (21519001) found no significant difference in clinician impression ($p = 0.097$), though a non-significant trend favored donepezil. These conflicting results create uncertainty about the overall effect.
- ****Full Answer**:** The rate of clinician impression of cognitive change was higher with donepezil in one trial [15534239] but showed no significant difference in another larger trial [21519001], leading to conflicting evidence.

- **Answer**: Uncertain Effect

Remarks: In the original SR, the formal meta-analysis reveals an overall statistically significant effect on the clinician impression of cognitive change. DeepSeek R1 only tries to directly compare the two individual papers, and this simple strategy fails to correctly resolve the seemingly conflicting evidence.

Question ID 27 - 0/24 models correct

Review PMID: 26447539

Question: Is fatigue severity higher, lower, or the same when comparing doxepin to placebo?

Correct Answer: insufficient data

PMIDs of Relevant Sources: 23561946

DeepSeek-R1 Response:

- **Rationale**: The study (Article ID 23561946) compared doxepin to placebo in Parkinson's patients with insomnia and measured fatigue severity as a secondary outcome. Results showed that doxepin significantly reduced the fatigue severity scale compared to placebo ($p = 0.02$), indicating lower fatigue severity in the doxepin group.
- **Full Answer**: Fatigue severity was lower with doxepin compared to placebo, as evidenced by a statistically significant reduction in the fatigue severity scale [23561946].
- **Answer**: Lower

Remarks: The SR authors find 12 patients to be an insufficient sample size to make a conclusive evaluation of fatigue severity, while DeepSeek R1 blindly trusts the authors of the paper. This type of failure highlights that models may be too easily swayed by the style in which the scientific papers are written.

S.2.3 LLAMA 3.0 8B

Question ID 56 - 3/24 models correct

Review PMID: 27782297

Question: Is the risk of treatment-related sore throat/dry mouth higher, lower, or the same when comparing botulinum toxin type A (BtA) to botulinum toxin type B (BtB)?

Correct Answer: lower

PMIDs of Relevant Sources: 16275831, 18098274

Llama 3.0 8B Response:

- **Rationale**: The question asks whether the risk of treatment-related sore throat/dry mouth is higher, lower, or the same when comparing botulinum toxin type A (BtA) to botulinum toxin type B (BtB). To answer this question, we need to analyze the adverse events reported in the two articles.
- **Full Answer**: According to Article ID 16275831, dry mouth was more frequent with BoNTB (80%) compared to BoNTA (41%) [1]. In Article ID 18098274, mild dry mouth was more frequent with BoNTB, but there were no differences for moderate/severe dry mouth [2]. There is no mention of sore throat in either article.
- **Answer**: Based on the available data, the risk of treatment-related dry mouth is higher with BtB compared to BtA. However,

there is no data on sore throat to make a comparison. Therefore, the answer is: Higher (for dry mouth) and Insufficient Data (for sore throat).

Remarks: Llama 3.0 often fails to follow the instruction format, and in particular, does so while failing to conclusively pick a side for its final evaluation.

Question ID 94 - 17/24 models correct

Review PMID: 30746689

Question: Is the likelihood of disease-free survival higher, lower, or the same when comparing nerve-sparing radical hysterectomy to standard radical hysterectomy?

Correct Answer: no difference

PMIDs of Relevant Sources: 25872890

Llama 3.0 8B Response:

Based on the new context, I refined the original summary as follows:

****Rationale**:** To answer this question, I will analyze the article summaries to identify the outcomes related to disease-free survival in patients undergoing nerve-sparing radical hysterectomy (NSRH) versus standard radical hysterectomy (SRH).

****Full Answer**:** A systematic review and meta-analysis published in [1] found that NSRH was associated with a significantly higher rate of disease-free survival at 3 years (RR 1.23, 95% CI 1.04-1.46) compared to SRH. Another study published in [3] reported that NSRH resulted in a higher rate of disease-free survival at 5 years (HR 1.34, 95% CI 1.06-1.69) compared to SRH. However, a randomized controlled trial published in [2] found no significant difference in disease-free survival between NSRH and SRH at 2 years (HR 0.93, 95% CI 0.65-1.34).

****Answer**:** ****Higher**.** The majority of the studies suggest that NSRH is associated with a higher likelihood of disease-free survival compared to SRH, although the evidence is not uniform and the results may vary depending on the specific population and follow-up period.

****Refined Summary**:** The available evidence suggests that nerve-sparing radical hysterectomy (NSRH) may be associated with a higher rate of disease-free survival compared to standard radical hysterectomy (SRH), particularly at longer follow-up periods. However, the evidence is not uniform, and the results may vary depending on the specific population and follow-up period. A recent randomized controlled trial published in [2] found no significant difference in disease-free survival between NSRH and SRH at 2 years, but other studies have reported higher rates of disease-free survival with NSRH at 3 and 5 years.

****Additional Insights**:** The study published in [1] found that NSRH was associated with a higher rate of disease-free survival at 3 years, which was consistent with the findings of another study published in [3]. However, the study published in [2] found no significant difference in disease-free survival between NSRH and SRH at 2 years. The results of these studies suggest that NSRH may be associated with a higher likelihood of disease-free survival compared to SRH, but the evidence is not uniform and

the results may vary depending on the specific population and follow-up period.

****Conclusion**:** The available evidence suggests that NSRH may be associated with a higher rate of disease-free survival compared to SRH, particularly at longer follow-up periods. However, the evidence is not uniform, and the results may vary depending on the specific population and follow-up period. Further research is needed to confirm these findings and to determine the optimal surgical approach for patients with cervical cancer.

****Additional Context**:** The study published in [2] found that NSRH was associated with improved urinary function and reduced symptoms of urinary incontinence compared to SRH. This suggests that NSRH may be a more effective surgical approach for patients with cervical cancer, particularly those who are at risk of developing urinary incontinence.

Remarks: The output from Llama 3.0 shows that it is relying on or biased by internal memory in answering the questions on this dataset; we note that this question involves only one source, so there should not be multiple sources being cited.

S.2.4 LLAMA 4 SCOUT

Question ID 8 - 2/24 models correct

Review PMID: 28898386

Question: Is the length of hospital stay higher, lower, or the same when comparing Pancreatojejunostomy (PJ) to Pancreatogastrostomy (PG)?

Correct Answer: no difference

PMIDs of Relevant Sources: 16327486, 19092337, 7574936

Llama 4 Scout Response:

To answer the question of whether the length of hospital stay is higher, lower, or the same when comparing Pancreatojejunostomy (PJ) to Pancreatogastrostomy (PG), let's analyze the provided article summaries.

- ****Article ID 16327486**:** This study found that the mean postoperative hospitalization period stay was comparable in both groups, indicating no significant difference in hospital stay length between PJ and PG.
- ****Article ID 19092337**:** This study reported a mean hospital stay of 12 +/- 2 days after PPPD-GP (PG) and 16 +/- 3 days after PPPD-PJ (PJ), suggesting that the hospital stay was lower for PG compared to PJ.
- ****Article ID 7574936**:** This study noted that pancreatic fistula was associated with a significant prolongation of postoperative hospital stay but did not find a significant difference in the incidence of pancreatic fistula between the PG and PJ groups. However, it did not provide a direct comparison of mean hospital stays between the two groups.

Given these findings:

- ****Rationale**:** The rationale is based on the comparison of hospital stay lengths between PJ and PG across the provided

studies. While one study found no difference, another study clearly indicated a shorter hospital stay for PG.

- ****Full Answer****:
- [16327486] found no difference in hospital stay.
- [19092337] found a lower hospital stay for PG (12 +/- 2 days) compared to PJ (16 +/- 3 days).
- [7574936] did not provide a direct comparison but discussed complications.
- ****Answer****: Lower.

The conclusion that the length of hospital stay is lower for PG compared to PJ is primarily supported by [19092337], which directly compared hospital stays and found a significant difference. The other studies either found no difference or did not directly compare hospital stay lengths as primary outcomes. Therefore, based on the information provided:

The final classification is: ****Lower****.

Remarks: As with previous models, unlike the SR authors that perform a full meta-analysis and explicitly pool together the data from sources, Llama 4 scout fails to reconcile conflicting evidence, in this case seeming to just pick one source it trusts the most.

Question ID 219 - 11/24 models correct

Review PMID: 27056645

Question: Is the risk of adverse events higher, lower, or the same when comparing chromoscopy to conventional endoscopy?

Correct Answer: insufficient data

PMIDs of Relevant Sources: 12196768, 14960519, 20179689, 16527699, 21159889, 16767577, 19139000

Llama 4 Scout Response:

To answer the question of whether the risk of adverse events is higher, lower, or the same when comparing chromoscopy to conventional endoscopy, let's analyze the provided article summaries.

Step 1: Identify Relevant Information

The articles provided compare chromoscopy (or high-definition chromocolonoscopy) with conventional endoscopy in terms of detection rates of adenomas and other lesions. However, to assess the risk of adverse events, we need to focus on complications, side effects, or any negative outcomes reported.

2: Analyze Each Article for Adverse Events

- Article ID 12196768: "There were no complications."
- Article ID 14960519: No specific mention of adverse events.
- Article ID 20179689: No significant differences in adverse events; the study focuses on detection rates.
- Article ID 16527699: No specific mention of adverse events.
- Article ID 21159889: Mean extubation times were slightly but significantly longer in the PCC group, but no specific adverse events were mentioned.
- Article ID 16767577: The study mentions a significant difference in examination duration but does not specify adverse events.

- Article ID 19139000: Chromoendoscopy was associated with more normal tissue biopsies and longer procedure times but does not specify significant adverse events.

3: Determine the Risk of Adverse Events

From the provided summaries, only Article ID 12196768 explicitly states that "There were no complications," directly addressing adverse events. Other articles may imply potential for increased risk due to longer procedure times or more biopsies but do not explicitly report a higher incidence of adverse events.

4: Conclusion

Given the information, most studies do not report a significant increase in adverse events with chromoscopy compared to conventional endoscopy. The explicit mention of "no complications" in one study and the lack of detailed adverse event reporting in others suggest that there is not a clearly documented higher risk of adverse events with chromoscopy.

- ****Rationale****: The provided article summaries do not detail a significant increase in adverse events when comparing chromoscopy to conventional endoscopy. Only one study explicitly mentions no complications, and others focus on detection rates without highlighting adverse events.
- ****Full Answer****: The risk of adverse events is not significantly higher with chromoscopy compared to conventional endoscopy based on the provided summaries [12196768]. Some studies note longer procedure times or more biopsies, which could potentially increase the risk of adverse events, but significant differences are not commonly reported.
- ****Answer****: No Difference.

Remarks: The original SR authors recognize that no studies report on adverse events. Reading the logs closely, Llama 4 seems to also recognize this fact, but then concludes that this means there should be no significant difference in risk, highlighting a difference in how models (fail to) assess potential risks relative to human clinicians.

S.2.5 OPENBIOLLM-8B

Question ID 13 - 22/24 models correct

Review PMID: 29489032

Question: Is food intake higher, lower, or the same when comparing grehlin to placebo?

Correct Answer: higher

PMIDs of Relevant Sources: 15181065

OpenBioLLM-8B Response:

****Rationale****: The study found that ghrelin significantly increased energy intake in cancer patients with anorexia, as evidenced by a 31% increase in energy intake during ghrelin infusion compared to saline control, with all patients consuming more food. Additionally, the meal appreciation score was higher with ghrelin treatment. These results suggest that ghrelin could be an effective treatment for cancer anorexia and potentially other conditions with appetite loss. ****Full Answer****: The food intake is higher in ghrelin than in placebo, as demonstrated by a 31% increase in energy intake during ghrelin infusion compared to saline control, with all patients eating more and a higher meal appreciation score. [15181065]

Remarks: Some of OpenBioLLM's answers are correct when you read through them manually, but it clearly struggles to follow the required format, leading to answers marked incorrect.

Question ID 3 - 11/24 models correct

Review PMID: 25734590

Question: Is the rate of patient self-reported impression of memory change higher, lower, or the same when comparing cholinase inhibitors to placebo in patients with MS?

Correct Answer: uncertain effect

PMIDs of Relevant Sources: 15534239, 21519001

OpenBioLLM-8B Response:

The rate of patient self-reported impression of memory change is higher when comparing cholinase inhibitors to placebo in patients with MS.

Remarks: Even ignoring formatting errors, though, OpenBioLLM-8B sometimes comes to incorrect conclusions with little provided rationale.

T INDIVIDUAL CONFUSION MATRICES FOR ALL MODELS




Figure 24: Confusion matrix for DeepSeek R1.




Figure 25: Confusion matrix for DeepSeek V3.




Figure 26: Confusion matrix for GPT-4.1.




Figure 27: Confusion matrix for GPT-4.1 mini.




Figure 28: Confusion matrix for GPT-o1.




Figure 29: Confusion matrix for GPT-oss-120B.




Figure 30: Confusion matrix for HuatuoGPT-o1-70B.




Figure 31: Confusion matrix for HuatuoGPT-o1-7B.




Figure 32: Confusion matrix for Llama 3.0 70B.




Figure 33: Confusion matrix for Llama 3.0 8B.




Figure 34: Confusion matrix for Llama 3.1 405B.




Figure 35: Confusion matrix for Llama 3.1 70B.




Figure 36: Confusion matrix for Llama 3.1 8B.




Figure 37: Confusion matrix for Llama 3.3 70B (R1-Distill).




Figure 38: Confusion matrix for Llama 3.3 70B-Instruct.




Figure 39: Confusion matrix for Llama 4 Maverick.




Figure 40: Confusion matrix for Llama 4 Scout.




Figure 41: Confusion matrix for OpenBioLLM 70B.




Figure 42: Confusion matrix for OpenBioLLM 8B.




Figure 43: Confusion matrix for OpenThinker2-32B.




Figure 44: Confusion matrix for QwQ-32B.




Figure 45: Confusion matrix for Qwen2.5-32B-Instruct.




Figure 46: Confusion matrix for Qwen2.5-72B-Instruct.




Figure 47: Confusion matrix for Qwen2.5-7B-Instruct.




Figure 48: Confusion matrix for Qwen3-235B-A22B-FP8.